Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Takeda Supports the Canadian IBD Research Consortium's $1 Million Pioneer Grant for Second Year | ||||
By: PR Newswire Association LLC. - 13 Feb 2024 | Back to overview list |
|||
Funding to attract and advance Canadian clinical research in inflammatory bowel disease TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year. This grant, with Takeda contributing $500,000 of the $1,000,000 award, will continue to support high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD). "At Takeda, our unwavering dedication lies in making a tangible difference in the lives of Canadians struggling with inflammatory bowel disease," said Rute Fernandes, President & General Manager, Takeda in Canada. "In order to do this, we must continue to invest in scientific research that address the needs of patients, and that is why we are pleased to continue to support this important program." For the second PIONEER grant, a prospective, multi-site, randomized controlled trial (RCT) will be given priority, but one or multiple non-RCT designs will be considered, and to involve CIRC members. Investigators who have pilot data and partner support are encouraged to share those details. Requests for up to $1 million in funding will be considered, which can be dispersed over a minimum of two and a maximum of five years. "The purpose of CIRC is to advance the care of people living with Crohn's disease and Ulcerative Colitis, through research," said Dr. Talat Bessissow, President of CIRC and Gastroenterologist at McGill University. "We are immensely proud of our research community, this program and are grateful for Takeda partnership and dedication to advancing research in Canada." The inaugural PIONEER grant was awarded to Dr. Christopher Ma, Associate Professor of Medicine and Community Health Sciences, for his PATHFINDER study, a randomized, multi-centre pragmatic trial that will investigate which class of biologics is the optimal first-line treatment for patients with high-risk ileal Crohn's disease. "In Canada, there is significant competition for high-impact clinical research funding and a huge appetite amongst researchers, physicians, and patients to advance the field," said Dr. Ma. "The PIONEER Grant, established through $1,000,000 in support from Takeda, gives Canadian IBD researchers an amazing and truly unique opportunity to conduct practice changing investigator-initiated research. We are seeing firsthand the impact of this grant on our research community, with recruitment having already kicked off and most sites for the PATHFINDER study being set to open in 2024." Inflammatory bowel disease – the main forms of IBD being Crohn's disease and ulcerative colitis – causes chronic inflammation of the gastrointestinal (GI) tract which impacts food digestion, nutrition absorption and waste elimination for those affected. More than 300,000 Canadians live with this disease for which there is currently no cure.i ii Letters of intent are now being accepted and are due March 26th, 2024, at 12:00 am EST. Further details including information on how to submit a letter of intent can be found at: https://circ-ccrm.ca/pioneer-grant/. About CIRC About Crohn's and Colitis Canada About Takeda Canada Inc.
SOURCE Takeda Canada, Inc. |
||||
|
||||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |